← Back to Clinical Trials
Recruiting NCT07189078

NCT07189078 IntHyx : Intubation Strategies for Patients With Acute Hypoxemic Respiratory Failure

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07189078
Status Recruiting
Phase
Sponsor University Hospital, Angers
Condition Acute Hypoxemic Respiratory Failure
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2025-12-13
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Restrictive intubation strategyLiberal intubation strategy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2025-12-13 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Acute hypoxemic respiratory failure requires endotracheal intubation and invasive mechanical ventilation in approximately 30-40% of cases, due to severe hypoxemia and/or clinical signs of acute respiratory distress. The primary objectives of invasive mechanical ventilation are to reduce respiratory effort and improve oxygenation. However, this intervention is also associated with both direct and indirect adverse effects, mainly linked to the need for sedation and often neuromuscular blockade. These include hemodynamic compromise, neuromuscular weakness, ventilator-induced lung injury, and infectious complications. An ideal intubation strategy would therefore strike a balance: avoiding the risks of delayed intubation-such as refractory hypoxemia, excessive respiratory effort, and patient self-inflicted lung injury (P-SILI)-while limiting complications associated with invasive mechanical ventilation by withholding it in patients who might otherwise recover without. To date, the optimal strategy for achieving this risk-benefit balance remains uncertain. Clinical practice suggests a broad consensus on the necessity of intubation when so-called safety criteria are met: severe hypoxemia (SaO₂/FiO₂ ratio \< 88), marked respiratory distress (use of accessory muscles, thoracoabdominal paradox, respiratory rate \> 40/min), extra-respiratory manifestations of hypoxia (e.g., altered consciousness), and/or uncontrolled hemodynamic instability. Beyond these safety thresholds, however, debate persists. Some advocate for earlier intubation-a so-called liberal approach-triggered by predefined hypoxemia criteria (e.g., SpO₂/FiO₂ \< 110), with the aim of limiting the deleterious consequences of sustained hypoxemia. In routine practice, the criteria guiding intubation vary widely between clinicians and cannot be attributed to strong scientific evidence. This study therefore seeks to compare, in a randomized interventional design, the two main strategies currently applied across centers: * Liberal intubation strategy: prioritizing the prevention of organ dysfunction related to hypoxemia (notably hypoxic cardiac arrest) and the risk of P-SILI. * Restrictive intubation strategy: prioritizing the reduction of invasive mechanical ventilation use, with the goal of minimizing ventilation-related harm and its associated therapeutic burden.

Eligibility Criteria

Inclusion Criteria: * Adult patient * Patient admitted to intensive care less than 24 hours ago * Acute respiratory failure with hypoxemia defined by either: * Oxygen therapy ≥ 10 L/min via high-concentration mask required for SpO2 ≥ 92% * High-flow oxygen therapy with FiO2 ≥ 50% required for SpO2 ≥ 92% * Informed consent of the patient or a trusted relative (when the patient is unable to give consent) Exclusion Criteria: * Acute hypercapnic respiratory failure (defined by PaCO2 \> 45 mmHg) * Cardiogenic pulmonary edema * Exacerbation of chronic respiratory disease * Respiratory failure requiring long-term oxygen therapy * Neuromuscular disease * Glasgow Coma Scale score ≤ 12 * Decision to intubate immediately * Invasive mechanical ventilation within the previous 7 days * Treatment limitation decisions for intubation * Person deprived of liberty by judicial or administrative decision : Person undergoing compulsory psychiatric care, person subject to legal protection measures, Pregnant, breastfeeding, or parturient patient

Contact & Investigator

Central Contact

Mathilde TAILLANTOU-CANDAU, Doctor

✉ Mathilde.Taillantou-candau@chu-angers.fr

📞 +33 (0)2 41 35 58 65

Principal Investigator

Mathilde TAILLANTOU-CANDAU, Doctor

PRINCIPAL INVESTIGATOR

University Hospital, Angers

Frequently Asked Questions

Who can join the NCT07189078 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Hypoxemic Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07189078 currently recruiting?

Yes, NCT07189078 is actively recruiting participants. Contact the research team at Mathilde.Taillantou-candau@chu-angers.fr for enrollment information.

Where is the NCT07189078 trial being conducted?

This trial is being conducted at Angers, France, Le Mans, France, Nantes, France, Orléans, France and 5 additional locations.

Who is sponsoring the NCT07189078 clinical trial?

NCT07189078 is sponsored by University Hospital, Angers. The principal investigator is Mathilde TAILLANTOU-CANDAU, Doctor at University Hospital, Angers. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology